interesting; Friday targrt pps raised from $6 to $7 and this this today?????? $7 is coming in next few months
January 24, 2014
09:26 EDT CTIC Cell Therapeutics price target raised to $7 from $6 at Roth Capital
Roth Capital increased its price target on Cell Therapeutics as the firm thinks the company's AK2/FLT3 inhibitor, Pacritinib, is evolving quite favorably. The firm believes that two of the company's other drugs, ixuvri and tosedostat, have positive potential. Roth reiterates a Buy rating on the stock.